Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Novel transcatheter tricuspid valve devices from Abbott Laboratories and Edwards Lifesciences have been enrolled as pilot cases in CMS’ new Transitional Coverage for Emerging Technologies (TCET) pathway.
Conceived in the Stanford Biodesign Program, ENT start-up Spirair offers a breath of fresh air in the treatment of nasal septal deviation.
With a suite of minimally invasive reproductive-assist devices, Femasys may be poised to be the first big success in women's health. Excerpted from our recent feature article.